Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Receivables (2016 - 2026)

Champions Oncology has reported Receivables over the past 16 years, most recently at $18.2 million for Q1 2026.

  • For Q1 2026, Receivables fell 15.52% year-over-year to $18.2 million; the TTM value through Jan 2026 reached $18.2 million, down 15.52%, while the annual FY2025 figure was $16.6 million, 7.34% up from the prior year.
  • Receivables for Q1 2026 was $18.2 million at Champions Oncology, down from $18.7 million in the prior quarter.
  • Over five years, Receivables peaked at $21.6 million in Q1 2025 and troughed at $11.7 million in Q4 2023.
  • A 5-year average of $14.9 million and a median of $13.8 million in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: surged 96.98% in 2022 and later decreased 15.52% in 2026.
  • Year by year, Receivables stood at $13.3 million in 2022, then decreased by 12.12% to $11.7 million in 2023, then skyrocketed by 46.16% to $17.1 million in 2024, then grew by 9.39% to $18.7 million in 2025, then fell by 2.61% to $18.2 million in 2026.
  • Business Quant data shows Receivables for CSBR at $18.2 million in Q1 2026, $18.7 million in Q4 2025, and $15.8 million in Q3 2025.